Acquisitions24 Sept 2026, 10:05 pm
Dr. Lal PathLabs Acquires 70% Stake in SN Gene for Up to ₹168 Cr
AI Summary
Dr. Lal PathLabs Ltd announced today the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene) for up to INR 168 Crores, plus performance-linked earn-out capped at INR 31.5 Crores. This strategic move aims to strengthen the company's genomics expertise and expand its advanced diagnostic service portfolio. SN Gene, specializing in diagnostics and genomics, had a turnover of INR 57.96 Crores in FY26. The acquisition is expected to be completed by November 30, 2026, and SN Gene will become a subsidiary of Dr. Lal PathLabs post-completion. This transaction is not a related party transaction.
Key Highlights
- Acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores.
- Strategic move to enhance genomics expertise and diagnostic service portfolio.
- SN Gene had FY26 turnover of INR 57.96 Crores.
- Acquisition expected to be completed by November 30, 2026.
- SN Gene will become a subsidiary post-acquisition.
Price Impact
More from LALPATHLAB